Journey MedicalDERM
DERM
About: Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Employees: 41
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
102% more capital invested
Capital invested by funds: $14.8M [Q4 2024] → $30M (+$15.2M) [Q1 2025]
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4.27% more ownership
Funds ownership: 25.44% [Q4 2024] → 29.71% (+4.27%) [Q1 2025]
3% more funds holding
Funds holding: 37 [Q4 2024] → 38 (+1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for DERM.
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
Neutral
Seeking Alpha
1 month ago
Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srinivas Sidgiddi - Vice President, Research and Development Ramsey Alloush - Chief Operating Officer and General Counsel Conference Call Participants Scott Henry - AGP Kalpit Patel - B. Riley Securities Thomas Flatten - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by.
Positive
Zacks Investment Research
1 month ago
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET
Positive
Zacks Investment Research
1 month ago
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Negative
Benzinga
2 months ago
Top 3 Health Care Stocks That May Crash In Q2
As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Positive
Zacks Investment Research
2 months ago
Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains?
Journey Medical (DERM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO”). Mr. Alloush will continue to also serve as the Company's General Counsel.
Neutral
Seeking Alpha
2 months ago
Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - Roth Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
Charts implemented using Lightweight Charts™